Investigating a Triple Therapy for HIV: PEG IL-2, Zidovudine, and Thymosin Alpha 1

The Acquired Immunodeficiency Syndrome (AIDS) is characterized by a significant reduction in T helper cell number and function, which are crucial components of the immune system. Thymosin alpha 1 is an immunomodulatory peptide believed to both increase IL-2 receptors on lymphocytes (a type of white blood cell) in laboratory settings and enhance lymphocyte maturation in living organisms. This study aimed to determine if thymosin alpha 1 could further enhance CD4 T cell levels and overall immune function in HIV-positive patients already receiving a combination of Zidovudine and PEG IL-2.

The provided research abstract focuses on the study's objectives and design, rather than presenting specific results from the completed trial. Therefore, detailed quantitative findings regarding the safety profile, specific changes in CD4 T cell counts, or alterations in viral load from this particular study abstract are not available. The study aimed to determine if the combination therapy could lead to an increase in IL-2 receptors and enhanced lymphocyte maturation, thereby improving immune responses in HIV-positive patients. While the specific outcomes are not detailed here, the trial was designed to quantitatively compare the effects of this triple therapy on immune parameters against baseline or control expectations. > The primary goal was to establish the safety of the combined regimen of Thymosin alpha 1, Zidovudine, and PEG IL-2, and to assess its potential to positively influence immunologic and pharmacokinetic markers in both asymptomatic and symptomatic HIV-infected individuals.